Australia is initiating a groundbreaking program to combat peanut allergies in infants by offering a structured oral immunotherapy treatment under the supervision of select pediatric hospitals.

Eligible babies will receive gradually increasing doses of peanut powder over at least two years to build immunity and reduce sensitivity.

This approach, which has been available in clinical trials and specialist centers globally, is being adopted as a national model for the first time.

The program aims to increase the tolerance threshold in infants, potentially allowing them to consume peanuts freely or reduce the risk of severe reactions from accidental exposure.

The program will be closely monitored for safety and effectiveness, with hopes of expansion.

Families are cautioned against attempting such treatments unsupervised at home.


(colombotimes.lk)